Grant: Project Grant

Here, we describe a class of novel drug-like molecules that potently and selectively kill both Her2+ and triple negative breast cancer cells over normal healthy cells. These molecules target a protein called STAT3, that has been shown to play a key role in tumour progression and survival. Most excitingly, these molecules, when given to mice bearing aggressive human tumours, completely halt tumour growth, and at the same time, trigger the immune system to attack the tumour cells and accelerate the tumour clearance. We believe this represents an exciting new therapy for breast tumours with a poor prognosis. In this proposal, we aim to optimize the drug-like properties of these molecules and identify an advanced preclinical candidate for triple negative and Her2+ breast cancer.